Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Medimabbio Inc. has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This matter is being handled by 1 distinct examiner in 1 distinct art unit. The prosecution profile is currently limited to this single active engagement, which allows for a highly focused and resource-efficient approach. Practitioners can concentrate their efforts on the specific preferences and past rulings of the assigned examiner to maximize the chances of a favorable outcome. This singular focus in the Biotechnology & Pharmaceuticals area suggests that the company is prioritizing a specific biological innovation.
HADDAD, MAHER M is the busiest examiner, currently managing 1 pending office action. Because there is only 1 distinct examiner and 1 distinct art unit involved, the company avoids the complexity of managing multiple examiner personalities or differing art unit standards. The presence of only 1 pending office action simplifies the tracking of deadlines and the preparation of responses. Practitioners should treat this 1 pending office action as a critical component of the company's current intellectual property strategy, given its status as the only active office action. The outcome of this matter will significantly impact the company's patent position in this technology sector. This concentrated effort allows for a more efficient use of legal resources and a more direct path to potential allowance.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| HADDAD, MAHER M | 1 | 50.6% | +53.8% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18290178 | ANTI-GITR ANTIBODIES AND USES THEREOF | HADDAD, MAHER M | — |
| Art Unit | Apps |
|---|---|
| 1641 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18290178 | ANTI-GITR ANTIBODIES AND USES THEREOF | HADDAD, MAHER M | 1641 | §112 | Non-Final OA | — | Pending | Nov 10, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialMedimabbio Inc. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Maher M Haddad has the most, with 1 of Medimabbio Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
